글로벌 시각 장애 시장 – 2029년까지의 산업 동향 및 예측

글로벌 시각 장애 시장 분석 및 규모

최근 몇 년 동안 시력 장애 시장은 예측 기간 동안 빠르게 성장할 것으로 예상됩니다. 시각 장애는 전혀 또는 부분적으로 시력을 잃을 수 없는 것을 포함하여 모든 유형의 시력 상실을 의미할 수 있습니다. 백내장, 약시, 당뇨망막병증, 녹내장 , 황반변성 및 기타 장애는 출생 후 시력 상실을 일으킬 수 있습니다. 이미지를 처리하는 눈이나 뇌의 한 요소 이상이 아프거나 손상되면 심각하거나 완전한 시력 상실이 발생할 수 있습니다. 많은 경우 의료 치료, 수술 또는 안경이나 콘택트렌즈와 같은 교정 렌즈로는 시력을 회복하기에 충분하지 않습니다. 시각 장애에 대한 보조 기술은 이러한 시각 장애의 경우 활용할 수 있습니다. 이 시각 장애 보조 기술은 장애인을 위한 재활, 적응 또는 보조 장치로 사용할 수 있습니다.

• Data Bridge Market Research는 시각 장애 시장이 2021년에 4,738.0백만 달러 규모였으며 2029년까지 9,167.14백만 달러에 도달할 것으로 예상되며 2022년에서 2029년까지의 예측 기간 동안 8.60%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

글로벌 시각 장애 시장 정의

시력 장애는 일반적으로 시력 상실로 알려져 있으며, 사물을 인식할 수 없거나 감소된 능력을 특징으로 하는 일련의 질병을 말합니다. 이는 다양한 눈 질환과 외상 및 뇌 손상으로 인해 발생하며, 이로 인해 전달 뉴런이 병들고 손상됩니다. 시력 장애는 환자의 삶의 질에 다양한 영향을 미칠 수 있습니다. 결과적으로 새로운 치료법에 대한 연구를 계속하는 것이 중요합니다.

보고 범위 및 시장 세분화

시각 장애 시장 역학

운전자

• 시각 장애 및 실명의 증가 추세

시각 장애와 실명의 증가는 글로벌 시각 장애 시장 성장의 주요 원동력입니다. 세계보건기구(WHO)에 따르면, 2019년에 전 세계적으로 최소 10억 명이 근거리 또는 원거리 시력 장애를 겪었습니다.

• 의료 인프라에 대한 투자 증가

시각 장애인 시장의 성장률에 영향을 미치는 또 다른 중요한 요인은 의료 서비스 지출이 증가하고 있다는 점인데, 이는 인프라 개선에 도움이 됩니다.

• 보조 기술 에 대한 수요 증가

보조 기술에 대한 수요 증가는 시장 성장률을 촉진할 것입니다. 당뇨망막병증, 굴절 이상, 녹내장, 백내장, 연령 관련 황반변성과 같은 안구 질환의 유병률이 증가함에 따라 시각 장애에 대한 보조 기술에 대한 필요성도 증가할 것입니다.

또한, 공공 및 민간 기관에서 인식을 확산하기 위한 이니셔티브가 증가함에 따라 시각 장애 시장이 확대될 것입니다. 또한, 높은 가처분 소득과 첨단 치료 및 혁신적 솔루션에 대한 수요 증가로 인해 시각 장애 시장이 확대될 것입니다. 이와 함께 노령 인구 증가와 사람들의 라이프스타일 변화로 인해 시장 성장률이 향상될 것입니다.

기회

• 연구개발 활동의 증가       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the vision impairment market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment in the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the vision impairment market growth during the forecast period.

Restraints/Challenges Global Vision Impairment Market

On the other hand, the high cost associated with the treatment of vision impairment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the vision impairment market. Additionally, the impact of COVID-19 on supply chain and strict regulatory guidelines will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This vision impairment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the vision impairment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Near or far vision impairment affects at least 2.2 billion individuals worldwide. Vision impairment may have been avoided or managed in at least 1 billion – or nearly half – of these cases. This 1 billion people include those with moderate to severe distance vision impairment or blindness due to diabetic retinopathy (3.9 million), uncorrected refractive error (88.4 million), corneal opacities (4.2 million), cataract (94 million), trachoma (2 million) and glaucoma (7.7 million), as well as those with near vision impairment due to uncorrected presbyopia (826 million).

The vision impairment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, and adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Vision Impairment Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. According to a report by the World Health Organization, coronavirus illness (COVID-19) has infected about 68.1 million people worldwide as of December 10, 2020. Due to the rising prevalence of COVID-19, prominent companies in the visual impairment market are concentrating their efforts on the research and development of novel products to help support and combat COVID-19's effects. The COVID-19 outbreak influenced the world economy and, as a result, the market for visual impairment. Quarantines, travel restrictions, and social distancing measures are expected to cause a significant drop in corporate and consumer spending until the third quarter of 2020.

Global Vision Impairment Market Scope

The vision impairment market is segmented on the basis of type, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Macular Degeneration
• Retinitis Pigmentosa
• Refractive Errors
• Night Blindness
• Others

On the basis of type, the vision impairment market is segmented into macular degeneration, retinitis pigmentosa, refractive errors, night blindness and others.

Treatment

• Medications
• Devices
• Surgery
• Others

Based on treatment, the vision impairment market is segmented into medications, devices and surgery. The medication segment is further bifurcated into monoclonal antibodies, gene therapy and others. The device section has been categorized into eye lenses, implant and others.

Route of Administration

• Oral
• Topical
• Implant
• Intravitreal
• Others

The route of administration segment for the vision impairment market is segmented into oral, topical, implant, intravitreal and others.

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

On the basis of end-users, the vision impairment market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

On the basis of distribution channel, the vision impairment market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others

Vision Impairment Market Regional Analysis/Insights

The vision impairment market is analysed and market size insights and trends are provided by country, type, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the vision impairment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the vision impairment market because of the rising healthcare expenditure and growing prevalence of vision defects diseases in this region. Additionally, rising patient awareness will further propel the market’s growth rate in this region.

Europe is expected to grow during the forecast period due to rising number of cases of vision impairment population and presence of major key players in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Vision Impairment Market Share Analysis

The Vision impairment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to vision impairment market.

Some of the major players operating in the vision impairment market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd.(Jerusalem)
• Sanofi (France)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Eli Lilly and Company (US)
• Merck & Co., Inc. (US)
• Regeneron Pharmaceuticals Inc. (US)
• Allergan (Ireland)
• Neurotech, LLC (US)
• Gilead Sciences, Inc. (US)
• Adverum (US)
• STEMCELL Technologies Inc. (Canada)
• IVERIC bio (US)
• Kubota Pharmaceutical Holdings Co. Ltd. (US)
• Sanwa Kagaku Kenkyusho Co., Ltd (Japan)
• Opthea Limited (Canada)
• Santen Pharmaceutical Co., Ltd (Japan)
• PanOptica, Inc (US)
• Alcon (Switzerland)
• Phio Pharmaceuticals Corp (US)
• Bausch Health Companies Inc. (캐나다) 

SKU-53100